Książki na temat „Drug selection”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych książek naukowych na temat „Drug selection”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj książki z różnych dziedzin i twórz odpowiednie bibliografie.
Scotti, Marcus T., i Carolina L. Bellera, red. Drug Target Selection and Validation. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-95895-4.
Pełny tekst źródłaTrottet, Lionel, i Howard Maibach, MD. Dermal Drug Selection and Development. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-59504-7.
Pełny tekst źródłaMeeting, World Health Organization Expert Committee on the Selection and Use of Essential Medicines. The selection and use of essential medicines. Geneva: World Health Organization, 2003.
Znajdź pełny tekst źródłaWHO Expert Committee on the Selection and Use of Essential Medicines. The selection and use of essential medicines. Geneva: World Health Organization, 2004.
Znajdź pełny tekst źródłaPatrick, Augustijns, i Brewster Marcus, red. Solvent systems and their selection in pharmaceutics and biopharmaceutics. New York, NY: Springer, 2007.
Znajdź pełny tekst źródłaMasson, Alison. Generic substitution and prescription drug prices: Economic effects of state drug product selection laws. [Washington, D.C.?]: Bureau of Economics, Federal Trade Commission, 1985.
Znajdź pełny tekst źródłaSimons, David R. Hypertension: A physician's guide to drug selection and use. Boulder, Colo. (1550 Baseline Rd., Boulder 80302): Keyed Reviews Publications, 1986.
Znajdź pełny tekst źródłaVenitz, J., i W. Sittner, red. Appropriate Dose Selection — How to Optimize Clinical Drug Development. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-49529-1.
Pełny tekst źródłaParmeter, John E. Guide for the selection of drug detectors for law enforcement applications. Washington, DC: U.S. Dept. of Justice, Office of Justice Programs, National Institute of Justice, 2000.
Znajdź pełny tekst źródłaW, Murray Dale, Hannum D. W, National Institute of Standards and Technology (U.S.). Office of Law Enforcement Standards., National Institute of Justice (U.S.). Office of Science and Technology. i Law Enforcement and Corrections Standards and Testing Program (U.S.), red. Guide for the selection of drug detectors for law enforcement applications. Washington, DC: U.S. Dept. of Justice, Office of Justice Programs, National Institute of Justice, 2000.
Znajdź pełny tekst źródła1957-, Gibson Mark, red. Pharmaceutical preformulation and formulation: A practical guide from candidate drug selection to commercial dosage form. Englewood, CO: Interpharm Press, 2001.
Znajdź pełny tekst źródłaWorld Health Organization (WHO). The Selection and Use of Essential Medicines: Report of the WHO Expert Committee 2007. Geneva: World Health Organization, 2008.
Znajdź pełny tekst źródłaPauly, Mark V. Adverse selection and the challenges to stand-alone prescription drug insurance. Cambridge, Mass: National Bureau of Economic Research, 2003.
Znajdź pełny tekst źródłaD, Quick Jonathan, Management Sciences for Health (Firm) i Action Programme on Essential Drugs and Vaccines (World Health Organization), red. Managing drug supply: The selection, procurement, distribution, and use of pharmaceuticals. Wyd. 2. West Hartford, Conn., USA: Kumarian Press, 1997.
Znajdź pełny tekst źródłaAhn, Hyewon. Patentability of chemical selection inventions: The Olanzapine and Escitalopram decisions. Baden-Baden: Nomos, 2011.
Znajdź pełny tekst źródłaThe selection and use of essential medicines: Report of the WHO Expert Committee, 2009, (including the 16th model list of essential medicines and the 2nd WHO model list of essential medicines for children). Geneva: World Health Organization, 2009.
Znajdź pełny tekst źródłaOrganization, World Health, red. The selection and use of essential medicines: Report of the WHO Expert Committee 2015, (including the 19th WHO Model List of Essential Medicines and the 5th WHO Model List of Essential Medicines for Children). Geneva, Switzerland: World Health Organization, 2015.
Znajdź pełny tekst źródłaNebraska. 1989 state of Nebraska statutes, rules, and regulations relating to, pharmacy ; Nebraska Drug Product Selection Act. Lincoln, Neb: Dept. of Health, Bureau of Examining Boards, 1989.
Znajdź pełny tekst źródłaWHO Expert Committee on the Selection and Use of Essential Medicines. The selection and use of essential medicines: Report of the WHO Expert Committee, 2013 (including the 18th WHO Model List of Essential Medicines and the 4th WHO Model List of Essential Medicines for Children). Geneva, Switzerland: World Health Organization, 2014.
Znajdź pełny tekst źródłaLefevre, Ethan C. Food labelling: The FDA's role in the selection of healthy foods. New York: Nova Science Publishers, 2009.
Znajdź pełny tekst źródłaFood labelling: The FDA's role in the selection of healthy foods. New York: Nova Science Publishers, 2009.
Znajdź pełny tekst źródłaFishman, Marc. ASAM patient placement criteria: Supplement on pharmacotherapies for alcohol use disorders. Redaktor American Society of Addiction Medicine. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2010.
Znajdź pełny tekst źródłaCasey, Verna. The screening of employees: A selected bibliography. Monticello, Ill., USA: Vance Bibliographies, 1988.
Znajdź pełny tekst źródłaUnited States. Congress. Senate. Committee on the Judiciary. Mr. Robert Martinez to be director of National Drug Control Policy: Report together with supplemental, additional and minority views (to accompany the nomination of Mr. Bob Martinez to be director of National Drug Control Policy). [Washington, D.C.?: U.S. G.P.O., 1991.
Znajdź pełny tekst źródłaOffice, General Accounting. Drug war: Drug Enforcement Administration staffing and reporting in Southeast Asia : report to the Chairman and Ranking Minority Member, Committee on Government Operations, House of Representatives. Washington, D.C: U.S. General Accounting Office, 1992.
Znajdź pełny tekst źródłaUnited States. Congress. Senate. Committee on the Judiciary. Nomination of Robert Martinez to be director of the Office of National Drug Control Policy (drug czar): Hearings before the Committee on the Judiciary, United States Senate, One Hundred Second Congress, first session ... February 26 and 27, 1991. Washington: U.S. G.P.O., 1992.
Znajdź pełny tekst źródłaOffice, General Accounting. Drug war: Observations on counternarcotics aid to Colombia : report to Congressional requesters. Washington, D.C: U.S. General Accounting Office, 1991.
Znajdź pełny tekst źródłaWilliamson, Elizabeth M. Selection, preparation, and pharmacological evaluation of plant material. Chichester: J. Wiley, 1996.
Znajdź pełny tekst źródłaUnited States. Congress. Senate. Committee on the Judiciary. Confirmation hearing on the nomination of Asa Hutchinson to be Administrator of the Drug Enforcement Administration: Hearing before the Committee on the Judiciary, United States Senate, One Hundred Seventh Congress, first session, July 17, 2001. Washington: U.S. G.P.O., 2002.
Znajdź pełny tekst źródłaUnited Nations Dag Hammarskjold Library. Selective bibliography on drug abuse, drug traffic and drug control. [Geneva]: the Library, 1990.
Znajdź pełny tekst źródłaOffice, General Accounting. The drug war: U.S. programs in Peru face serious obstacles : report to congressional requesters. Washington, D.C: The Office, 1991.
Znajdź pełny tekst źródłaOffice, General Accounting. The drug war: U.S. programs in Peru face serious obstacles : report to Congressional requesters. Washington, D.C: U.S. General Accounting Office, 1991.
Znajdź pełny tekst źródłaUnited States. Congress. Senate. Committee on the Judiciary. Dr. William J. Bennett to be Director of National Drug Control Policy: Report together with additional and minority views (to accompany the nomination ...). [Washington, D.C.?: U.S. G.P.O., 1989.
Znajdź pełny tekst źródłaUnited States. Congress. Senate. Committee on the Judiciary. Dr. William J. Bennett to be Director of National Drug Control Policy: Report together with additional and minority views (to accompany the nomination ...). [Washington, D.C.?: U.S. G.P.O., 1989.
Znajdź pełny tekst źródłaJudiciary, United States Congress Senate Committee on the. Dr. William J. Bennett to be Director of National Drug Control Policy: Report together with additional and minority views (to accompany the nomination ...). [Washington, D.C.?: U.S. G.P.O., 1989.
Znajdź pełny tekst źródłaSelective toxicity: The physico-chemical basis of therapy. Wyd. 7. London: Chapman and Hall, 1985.
Znajdź pełny tekst źródłaUnited States. Congress. Senate. Committee on the Judiciary. Nominations of Robert S. Warshaw, to be Associate Director, and Thomas J. Umberg to be Deputy Director for Supply Reduction: Hearing before the Committee on the Judiciary, One Hundred Fifth Congress, first session ... both of the Office of National Drug Control Policy, November 6, 1997. Washington: U.S. G.P.O., 1998.
Znajdź pełny tekst źródłaUnited States. Congress. Senate. Committee on the Judiciary. Confirmation hearing on the nomination of John P. Walters to be Director of the Office of National Drug Control Policy: Hearing before the Committee on the Judiciary, United States Senate, One Hundred Seventh Congress, first session, October 10, 2001. Washington: U.S. G.P.O., 2002.
Znajdź pełny tekst źródłaReinhard, Sittl, i Budd Keith, red. Practice of transdermal pain therapy. Bremen: Uni-Med, 2005.
Znajdź pełny tekst źródłaUnited States. Congress. Senate. Committee on the Judiciary. Nomination of Barry R. McCaffrey to be Director of the National Drug Control Policy: Hearing before the Committee on the Judiciary, United States Senate, One Hundred Fourth Congress, second session ... February 27, 1996. Washington: U.S. G.P.O., 1997.
Znajdź pełny tekst źródłaUnited States. Congress. Senate. Committee on the Judiciary. Executive branch nominations: Hearing before the Committee on the Judiciary, United States Senate, One Hundred Seventh Congress, second session, March 5, 2002. Washington: U.S. G.P.O., 2003.
Znajdź pełny tekst źródłaUnited States. Congress. Senate. Committee on the Judiciary. Confirmation hearings of federal appointments to the Office of National Drug Control Policy (Bennett, Walton, and Morris): Hearings before the Committee on the Judiciary, United States Senate, One Hundred First Congress, first session ... March 1, 2, June 6, and September 20, 1989. Washington: U.S. G.P.O., 1991.
Znajdź pełny tekst źródłaUnited States. Congress. Senate. Committee on the Judiciary. Confirmation hearings of federal appointments to the Office of National Drug Control Policy (Bennett, Walton, and Morris): Hearings before the Committee on the Judiciary, United States Senate, One Hundred First Congress, first session, on the nominations of Dr. William J. Bennett to be Director ..., Reggie B. Walton to be Associate Director, and Stanley E. Morris to be Deputy Director ... March 1, 2, June 6, and September 20, 1989. Washington: U.S. G.P.O., 1991.
Znajdź pełny tekst źródłaUnited States. Congress. Senate. Committee on the Judiciary. Confirmation hearings of federal appointments to the Office of National Drug Control Policy (Bennett, Walton, and Morris): Hearings before the Committee on the Judiciary, United States Senate, One Hundred First Congress, first session, on the nominations of Dr. William J. Bennett to be Director ..., Reggie B. Walton to be Associate Director, and Stanley E. Morris to be Deputy Director ... March 1, 2, June 6, and September 20, 1989. Washington: U.S. G.P.O., 1991.
Znajdź pełny tekst źródłaUnited States. Congress. Senate. Committee on the Judiciary. Nomination of Lee Patrick Brown: Hearing before the Committee on the Judiciary, United States Senate, One Hundred Third Congress, first session, on the nomination of Lee Patrick Brown, to be Director of the Office of National Drug Control Policy, May 25, 1993. Washington: U.S. G.P.O., 1994.
Znajdź pełny tekst źródłaUnited States. Congress. House. Committee on Government Operations. Government Information, Justice, and Agriculture Subcommittee. INS technology selection: Hearing before a subcommittee of the Committee on Government Operations, House of Representatives, One Hundredth Congress, second session, May 12, 1988. Washington: U.S. G.P.O., 1988.
Znajdź pełny tekst źródłaUnited, States Congress House Committee on Government Operations Government Information Justice and Agriculture Subcommittee. INS technology selection: Hearing before a subcommittee of the Committee on Government Operations, House of Representatives, One Hundredth Congress, second session, May 12, 1988. Washington: U.S. G.P.O., 1988.
Znajdź pełny tekst źródłaUnited States. Congress. House. Committee on Government Operations. Government Information, Justice, and Agriculture Subcommittee. INS technology selection: Hearing before a subcommittee of the Committee on Government Operations, House of Representatives, One Hundredth Congress, second session, May 12, 1988. Washington: U.S. G.P.O., 1988.
Znajdź pełny tekst źródłaUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment. Senate confirmation of the FDA commissioner; and reauthorization of research activities by ADAMHA: Hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, Ninety-ninth Congress, second session, on H.R. 3909 ... March 6, 1986. Washington: U.S. G.P.O., 1986.
Znajdź pełny tekst źródłaE, Adams Gerald, i North Atlantic Treaty Organization. Scientific Affairs Division., red. Selective activation of drugs by redox processes. New York: Plenum Press, 1990.
Znajdź pełny tekst źródła